June 19, 2024

Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug

The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.Read MoreDrugs (Pharmaceuticals), Alzheimer’s Disease, Brain, Memory, Leqembi (Drug), Clinical Trials, Eli Lilly and Company, Biogen Inc, Eisai Co Ltd, Food and Drug Administration, United States, donanemab, your-feed-science, your-feed-healthcareNYT > Health

Leave a Reply

Your email address will not be published. Required fields are marked *